pubmed.ncbi.nlm.nih.gov

Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders - PubMed

️Wed Jan 01 2003

Review

Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders

Terry D Butters et al. Philos Trans R Soc Lond B Biol Sci. 2003.

Abstract

Glycosphingolipid (GSL) lysosomal storage disorders are a small but challenging group of human diseases to treat. Although these disorders appear to be monogenic in origin, where the catalytic activity of enzymes in GSL catabolism is impaired, the clinical presentation and severity of disease are heterogeneous. Present attitudes to treatment demand individual therapeutics designed to match the specific disease-related gene defect; this is an acceptable approach for those diseases with high frequency, but it lacks viability for extremely rare conditions. An alternative therapeutic approach termed 'substrate deprivation' or 'substrate reduction therapy' (SRT) aims to balance cellular GSL biosynthesis with the impairment in catalytic activity seen in lysosomal storage disorders. The development of N-alkylated iminosugars that have inhibitory activity against the first enzyme in the pathway for glucosylating sphingolipid in eukaryotic cells, ceramide-specific glucosyltransferase, offers a generic therapeutic for the treatment of all glucosphingolipidoses. The successful use of N-alkylated iminosugars to establish SRT as an alternative therapeutic strategy has been demonstrated in in vitro, in vivo and in clinical trials for type 1 Gaucher disease. The implications of these studies and the prospects of improvement to the design of iminosugar compounds for treating Gaucher and other GSL lysosomal storage disorders will be discussed.

PubMed Disclaimer

Cited by

Pharmacotherapy of Gaucher Disease: Current and Future Options.
Bennett LL, Fellner C. Bennett LL, et al. P T. 2018 May;43(5):274-309. P T. 2018. PMID: 29719368 Free PMC article.
Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases.
Pagano RE. Pagano RE. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):885-91. doi: 10.1098/rstb.2003.1275. Philos Trans R Soc Lond B Biol Sci. 2003. PMID: 12803922 Free PMC article. Review.
Neurobiology and cellular pathogenesis of glycolipid storage diseases.
Walkley SU. Walkley SU. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):893-904. doi: 10.1098/rstb.2003.1276. Philos Trans R Soc Lond B Biol Sci. 2003. PMID: 12803923 Free PMC article. Review.
A historical perspective of the glycosphingolipids and sphingolipidoses.
Watts RW. Watts RW. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):975-83. doi: 10.1098/rstb.2003.1280. Philos Trans R Soc Lond B Biol Sci. 2003. PMID: 12803932 Free PMC article.
Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.
van den Berg RJ, Wennekes T, Ghisaidoobe A, Donker-Koopman WE, Strijland A, Boot RG, van der Marel GA, Aerts JM, Overkleeft HS. van den Berg RJ, et al. ACS Med Chem Lett. 2011 Apr 7;2(7):519-22. doi: 10.1021/ml200050s. eCollection 2011 Jul 14. ACS Med Chem Lett. 2011. PMID: 24900342 Free PMC article.

References

1. Nat Rev Drug Discov. 2002 Jan;1(1):65-75 - PubMed
1. Glycobiology. 1999 Oct;9(10):961-78 - PubMed
1. Phytochemistry. 2001 Feb;56(3):265-95 - PubMed
1. J Neurosci Res. 1994 Jun 1;38(2):234-42 - PubMed
1. EMBO J. 1999 Jul 1;18(13):3546-57 - PubMed

Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders - PubMed